ArticleMaterials today. Bio2026
Hyaluronic acid-engineered copper sulfide nanoparticles as immunomodulatory metal sulfide photothermal agents for macrophage-assisted osteosarcoma therapy.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal sulfide nanomaterials have emerged as promising photothermal agents for cancer therapy owing to their strong near-infrared absorption, favorable biocompatibility, and tunable surface chemistry. However, insufficient tumor accumulation and limited immunological activation remain major obstacles restricting their therapeutic efficacy in solid tumors. Herein, we report a macrophage-assisted delivery strategy based on hyaluronic acid-engineered copper sulfide nanoparticles (HA@CuS NPs) for enhanced photothermal-immunotherapy against osteosarcoma. In this system, adoptively transferred RAW264.7 macrophages were intravenously administered to increase macrophage enrichment within the osteosarcoma microenvironment, while HA@CuS NPs were rationally designed to target both tumor cells and tumor-associated macrophages through HA-mediated cellular recognition. The HA-coated CuS nanoparticles displayed good colloidal stability, efficient near-infrared photothermal conversion, and enhanced cellular uptake by osteosarcoma cells and macrophages. Importantly, macrophages acted as cellular reservoirs for CuS nanoparticles, promoting tumor accumulation and improving intratumoral photothermal distribution. Under 808-nm laser irradiation, the combined macrophage/HA@CuS treatment produced stronger tumor heating and more effective osteosarcoma ablation than HA@CuS nanoparticles alone. Beyond direct photothermal killing, HA@CuS nanoparticles also remodeled the tumor immune microenvironment by promoting M1-like polarization of tumor-associated macrophages, increasing IL-12p40 secretion, reducing IL-10 levels, and enhancing cytotoxic T lymphocyte infiltration. These immune-regulatory effects further amplified the antitumor response induced by photothermal therapy. Collectively, this study demonstrates that HA-engineered copper sulfide nanoparticles can function not only as metal sulfide photothermal agents but also as immunomodulatory nanomaterials. The integration of macrophage-assisted tumor delivery with CuS-based photothermal therapy provides a promising strategy for improving the therapeutic efficacy of metal-based nanomedicine against osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.